文献速递肝病消化道肿瘤与早癌

肝细胞癌的炎症型与非炎症型:修订的免疫基因组学分类

Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.
PubMed 文献 · Gut · 2022-02-23

研究对240例肝细胞癌患者行RNA测序、全外显子测序、T细胞受体测序、多重免疫荧光和免疫组化,并在660例其他队列中验证,提出炎症型(37%)、中间型和排除型三类免疫基因组学分类,并描述两种与免疫逃逸相关的CTNNB1突变模式。

要点

  • 炎症型肝细胞癌占37%,含既往免疫亚型22%和新免疫样亚型15%。
  • 20基因特征可识别约90%的炎症型肿瘤,并与免疫治疗应答相关。
  • 排除型富集CTNNB1突变(93% vs 27%,p<0.001)和PTK2过表达。

核心结论

  • 研究刻画了肝细胞癌的免疫基因组学背景,定义了炎症型与非炎症型肿瘤。
  • 描述了两种与免疫逃逸中不同作用相关的CTNNB1模式。
  • 这些特征可能有助于预测肝细胞癌的免疫应答。

研究设计与样本

  • 研究对新队列240例肝细胞癌患者行RNA测序、全外显子测序、T细胞受体测序、多重免疫荧光和免疫组化。
  • 研究在其他包含660例患者的队列中验证了结果。

主要发现

  • 炎症型肝细胞癌占37%,包括既往报告的免疫亚型22%和新免疫样亚型15%,后者具有高干扰素信号、细胞溶解活性、免疫效应细胞因子表达和更多样化的T细胞库。
  • 20基因特征可捕获约90%的炎症型肿瘤,并与免疫治疗应答相关。
  • 液体活检中鉴定的蛋白可重现炎症型,ROC曲线下面积(AUC)为0.91。
  • 中间型富集TP53突变(49% vs 29%,p=0.035)和涉及免疫相关基因的染色体缺失。
  • 排除型富集CTNNB1突变(93% vs 27%,p<0.001)和因基因扩增及启动子低甲基化导致的PTK2过表达。

关键数值与推荐

  • 炎症型中TP53突变比较:中间型49% vs 其他29%(p=0.035)。
  • 排除型中CTNNB1突变比较:排除型93% vs 其他27%(p<0.001)。
  • 液体活检蛋白重现炎症型的AUC为0.91。
  • 20基因特征可捕获约90%的炎症型肿瘤。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We previously reported a characterisation of the hepatocellular carcinoma (HCC) immune contexture and described an immune-specific class. We now aim to further delineate the immunogenomic classification of HCC to incorporate features that explain responses/resistance to immunotherapy. DESIGN: We performed RNA and whole-exome sequencing, T-cell receptor (TCR)-sequencing, multiplex immunofluorescence and immunohistochemistry in a novel cohort of 240 HCC patients and validated our results in other cohorts comprising 660 patients. RESULTS: Our integrative analysis led to define: (1) the inflamed class of HCC (37%), which includes the previously reported immune subclass (22%) and a new immune-like subclass (15%) with high interferon signalling, cytolytic activity, expression of immune-effector cytokines and a more diverse T-cell repertoire. A 20-gene signature was able to capture ~90% of these tumours and is associated with response to immunotherapy. Proteins identified in liquid biopsies recapitulated the inflamed class with an area under the ROC curve (AUC) of 0.91; (2) The intermediate class, enriched in TP53 mutations (49% vs 29%, p=0.035), and chromosomal losses involving immune-related genes and; (3) the excluded class, enriched in CTNNB1 mutations (93% vs 27%, p<0.001) and PTK2 overexpression due to gene amplification and promoter hypomethylation. CTNNB1 mutations outside the excluded class led to weak activation of the Wnt-βcatenin pathway or occurred in HCCs dominated by high interferon signalling and type I antigen presenting genes. CONCLUSION: We have characterised the immunogenomic contexture of HCC and defined inflamed and non-inflamed tumours. Two distinct CTNNB1 patterns associated with a differential role in immune evasion are described. These features may help predict immune response in HCC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Montironi C, Castet F, Haber PK, et al. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut. 2022. PMID: 35197323. doi:10.1136/gutjnl-2021-325918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。